



PRESS RELEASE

www.discovery-evolution.com

Karl-Farkas-Gasse 18. 1030 Vienna, Austria

office@discovery-evolution.com

July 1st 2026

Vienna, Austria / Budapest, Hungary

STRT Invests in Discovery Evolution

to Advance the Next Generation of Digital Biologic Discovery

Discovery Evolution, the Vienna-based biotechnology company developing a digital-first platform for the discovery of biologics, today announced a strategic investment from STRT Invest, one of Central and Eastern Europe's leading early-stage technology investors. Financial terms of the investment were not disclosed.

The investment will support the continued advancement of Discovery Evolution's proprietary RedQueen platform and the initiation of the company's internal therapeutic discovery pipeline. By combining digital evolution, computational biophysics, and artificial intelligence, **RedQueen** enables the discovery of therapeutic

antibodies against some of the most challenging drug targets, including G protein-coupled receptors (GPCRs).

The partnership reflects a shared ambition to build globally competitive deep-tech companies originating from Central and Eastern Europe



Harold P. de Vladar
Founder & CEO
Discovery Evolution



Péter Balogh
CEO
STRT Invest

July, 2026



PRESS RELEASE

www.discovery-evolution.com

STRT Invest in Discovery Evolution

“Discovery Evolution represents exactly the kind of deep-tech innovation with global potential that STRT Invest specifically seeks in the Central and Eastern European region. By combining AI and digital modeling, the team is transforming a traditionally slow and expensive process, where time and cost savings can ultimately be measured in human lives. We are convinced that the **RedQueen** platform brings a new dynamic to complex drug discovery, and we are backing their international expansion with capital, an extensive network, and strategic support.” said **Peter Langmar, Investment Director of STRT Invest.**

Drug discovery remains a lengthy and expensive process, particularly for complex membrane proteins such as GPCRs, which account for approximately one-third of all approved drug targets yet remain difficult to address using conventional antibody discovery technologies. Discovery Evolution tackles this challenge by shifting much of the discovery process from the laboratory into a computational environment, dramatically accelerating candidate generation while reducing experimental costs.

“We are delighted to welcome STRT Invest as a strategic partner,” said **Harold P. de Vladár, Founder and CEO of Discovery Evolution.** “Beyond capital, STRT brings entrepreneurial experience, an exceptional network, and a long-term commitment to helping technology companies scale internationally. This investment strengthens our ability to further develop **RedQueen**, expand our discovery pipeline, and accelerate collaborations with pharmaceutical partners.”

Since its founding, Discovery Evolution has successfully generated and experimentally validated antibodies discovered through its RedQueen platform and continues to expand its capabilities in the discovery of therapeutics against GPCRs and other challenging membrane proteins. In parallel, the company has secured competitive non-dilutive funding from the Austrian Research Promotion Agency (FFG) and aws (Austria Wirtschaftsservice), providing further validation of its technology and supporting the continued development of its **RedQueen** platform and next-generation state-specific antibody discovery capabilities.



PRESS RELEASE

www.discovery-evolution.com

STRT Invest in Discovery Evolution

About **Discovery Evolution**

Discovery Evolution is a Vienna-based biotechnology company developing a digital-first platform for the discovery of biologics. Its proprietary **RedQueen** platform combines digital evolution, computational biophysics, and artificial intelligence to design therapeutic antibodies against challenging drug targets, particularly G protein-coupled receptors (GPCRs). By moving much of biologic discovery into the digital domain, the company aims to accelerate drug discovery while reducing cost and experimental complexity. Discovery Evolution collaborates with pharmaceutical and biotechnology partners worldwide while advancing its own therapeutic discovery pipeline.

www.discovery-evolution.com

Media Contacts

Discovery Evolution

Harold P. de Vladár

Founder & CEO

office@discovery-evolution.com

About **STRT Invest**

STRT Invest is one of Central and Eastern Europe's leading early-stage technology investors, supporting founders with capital, strategic guidance, and access to an extensive entrepreneurial network. As part of STRT Holding, the firm invests in scalable technology companies with international ambitions, helping build the next generation of globally successful businesses emerging from the region.

www.strtinvest.com

Media Contacts

STRT Invest

Istvan Toth

Public and Investor Relations

istvan.toth@strt.hu

July, 2026